Global Hepatitis B Vaccines Market Growth 2025-2031

The global Hepatitis B Vaccines market size is predicted to grow from US$ 1335 million in 2025 to US$ 1968 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.

Global key players of Hepatitis B Vaccines include GSK, Dynavax, NCPC, etc. The top three players hold a share about 64%. North America is the largest market for Hepatitis B Vaccines, which has a share about 45%, followed by Asia-Pacific and Europe with share 31% and 17%, separately. In terms of product type, Yeast Derived is the largest segment, occupied for a share of 85%. In terms of application, Adult is the largest field with a share about 64%.

LP Information, Inc. (LPI) ' newest research report, the “Hepatitis B Vaccines Industry Forecast” looks at past sales and reviews total world Hepatitis B Vaccines sales in 2024, providing a comprehensive analysis by region and market sector of projected Hepatitis B Vaccines sales for 2025 through 2031. With Hepatitis B Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis B Vaccines industry.

This Insight Report provides a comprehensive analysis of the global Hepatitis B Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hepatitis B Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatitis B Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis B Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis B Vaccines.

This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis B Vaccines market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Yeast Derived
CHO Derived

Segmentation by Application:
Children
Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
GSK
NCPC
Merck
Bio Kangtai
Dynavax
AIM Vaccine
KM Biologics
LG Life Sciences
Serum Institute

Key Questions Addressed in this Report

What is the 10-year outlook for the global Hepatitis B Vaccines market?

What factors are driving Hepatitis B Vaccines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Hepatitis B Vaccines market opportunities vary by end market size?

How does Hepatitis B Vaccines break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.